Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Building a Computational Model of Auditory Hallucinations (CLARITY WP1)

14 de setembro de 2026 atualizado por: King's College London

Building a Computational Model of the Role of Excitation/Inhibition (E/I) Balance in Auditory Hallucinations Using Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI): a Case-control Study

Some people hear voices or sounds that other people cannot hear; these are called auditory hallucinations. The study aims to understand what is happening in the brain when this occurs and will use brain scans to learn more. Greater understanding should help develop better treatments in the future.

Visão geral do estudo

Descrição detalhada

Psychotic disorders, including schizophrenia and bipolar disorder with psychotic features, are severe mental health conditions that significantly diminish quality of life and place a substantial economic burden on society. In England, the total societal cost of schizophrenia is estimated at £11.8 billion per year, with the public sector bearing approximately £7.2 billion of this cost. People with lived experience of psychosis (PWLEP) may experience a range of symptoms, including positive symptoms such as hallucinations and delusions, negative symptoms such as affective flattening, and cognitive impairments, including difficulties with attention, memory and executive function.

Auditory hallucinations, a common and disruptive symptom of psychotic disorders, are typically experienced as hearing voices and occur in approximately 75% of PWLEP. These voices are often intrusive and may be critical, threatening, or commanding, and can be associated with an increased risk of suicide. Whilst antipsychotic treatments, which primarily act through dopamine receptor antagonism, can be effective, they are often associated with significant side effects, and the response to antipsychotic treatment is insufficient in around 40% of patients. There is therefore an urgent need to better understand the mechanisms underlying auditory hallucinations to identify more effective treatment targets and develop novel therapies that act through mechanisms other than dopamine receptor antagonism.

A key avenue for understanding auditory hallucinations is examining disruptions in excitatory-inhibitory (E/I) balance, a fundamental mechanism in neural processing. Post-mortem and in vivo electrophysiological studies implicate dysregulated cortical microcircuits in psychosis, where excitatory pyramidal cells (signalling using glutamate) and inhibitory interneurons (signalling using gamma-aminobutyric acid or 'GABA') regulate neural activity. Interactions between these cells generate synchronised neural oscillations across different frequency bands, from low (delta, theta, alpha) to high (beta, gamma) frequencies. These oscillations, which are crucial for coordinating neural activity and supporting cognitive and perceptual function, can also serve as a measure of E/I balance and be assessed in humans using electroencephalography (EEG).

Previous studies have shown that resting-state cortical theta and gamma oscillations are increased, whilst beta oscillations and evoked gamma are reduced in people with psychosis, indicating altered E/I balance in the cortex. Dynamic causal modelling (DCM) is a validated computational technique for inferring E/I imbalance in both rodent models and humans, allowing a more precise estimate of E/I balance in the human brain to be obtained. Applying DCM to EEG and functional magnetic resonance imaging (fMRI) paradigms-including resting-state recordings, mismatch negativity (MMN), and the 40-Hz auditory steady-state response (ASSR)-has previously shown that pyramidal neuron disinhibition in the auditory cortex (primary auditory cortex and related regions) was associated with auditory perceptual symptoms, serving as a measure of hallucinations.

These findings have been demonstrated in those with chronic psychosis. The investigators now propose to measure E/I early in the presentation of a psychotic disorder to show whether this pathophysiology is related to symptoms demonstrated close to the onset of illness.

The aim of this study is to create a computational model of auditory hallucinations using cortical E/I balance in individuals with a psychotic disorder.

Primary Objective:

The principal research objective is to understand differences in brain signalling, specifically in E/I balance in those with auditory hallucinations using a computational model based on EEG measures such as ASSR relative to healthy volunteers without auditory hallucinations, and whether such measures predict changes in auditory hallucination over time.

Secondary Objectives:

The secondary research objectives include testing if levels of brain and blood substances and genetics are related to brain E/I balance in those with auditory hallucinations and healthy controls.

Tipo de estudo

Observacional

Inscrição (Estimado)

146

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: CLARITY Study Contact
  • Número de telefone: +447871777185
  • E-mail: clarity@kcl.ac.uk

Estude backup de contato

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Método de amostragem

Amostra Não Probabilística

População do estudo

PWLEP: people with auditory perceptual alterations able to get to the study site in London.

Controls: people without psychosis or auditory perceptual alterations able to get to the study site in London.

Descrição

Inclusion Criteria:

PWLEP:

  1. Age 16-65 years.
  2. A score of at least 3 on the state section of the Auditory Perceptual Trait and State scale (APTS).
  3. If using an antipsychotic drug, participants must be on a stable dose of any medication during the baseline measures.
  4. Sufficient understanding of the nature of the study and any hazards of participating in it, or suitable consultee who can understand this and provide an opinion of what the participant's wishes would be if the participant does not have capacity, if appropriate to do so.
  5. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire study.
  6. Capacity to give written consent to participate after reading the information and consent form and after having the opportunity to discuss the study with the investigators or their delegates, or suitable consultee who can understand this and provide an opinion of what the participant's wishes would be if the participant does not have capacity, if appropriate to do so.

Healthy controls:

  1. Age 16-65 years.
  2. Sufficient understanding of the nature of the study and any hazards of participating in it, or suitable consultee who can understand this and provide an opinion of what the participant's wishes would be if the participant does not have capacity, if appropriate to do so.
  3. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire study.
  4. Capacity to give written consent to participate after reading the information and consent form and after having the opportunity to discuss the study with the investigators or their delegates, or suitable consultee who can understand this and provide an opinion of what the participant's wishes would be if the participant does not have capacity, if appropriate to do so.

Exclusion Criteria:

PWLEP:

  1. Clinically relevant abnormal history, or laboratory values at the pre-study screening assessment or participation in other research studies that could interfere with the objectives of the study or the safety of the participant, as deemed significant for a study researcher.
  2. Impaired endocrine, cardiac, pulmonary, thyroid, haematological, hepatic, respiratory, neurological, immunological or renal function, or other major disease (e.g. cancer) deemed clinically significant at the time of the study.
  3. Recent history (i.e. in the last 12 months) of epilepsy or seizures.
  4. Homicidal ideation or intent, as judged by a researcher; suicidal ideation, with some intent to act, or suicidal behaviour, as judged by a researcher.
  5. History of drug or alcohol dependence (except for caffeine and nicotine and mild/moderate cannabis dependence) in the 3 months before study start.
  6. Likelihood that the participant will not comply with the requirements of the protocol.
  7. Contraindication to MRI, EEG or other study procedures (for example history of metal implants or metal pieces entering the body that cannot be removed safely, severe claustrophobia, allergy or skin sensitivity to EEG electrode gel).
  8. Any other condition or disability that would make participation in the study procedures not possible (for example severe vision or hearing impairment).

Healthy controls:

As above, and also:

1. No relevant family history of schizophrenia and psychosis (as judged relevant by a study researcher).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
People with lived experience of psychosis (PWLEP)
Age 16-65 years with experience of auditory perceptual alterations as measured by validated scale and able to consent to the study. On stable dose of antipsychotic medication if using. No recent history of epilepsy or seizure within last 12 months.
Control
Age 16-65 years with no relevant family history of schizophrenia and psychosis (as judged relevant by a study researcher) and able to consent to study. No recent history of epilepsy or seizure within last 12 months.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
E/I balance determined using the computational model based on the 40-Hz auditory steady-state response (ASSR) EEG response.
Prazo: Baseline
Computational model will be created after study end, using EEG data acquired at the baseline study visit.
Baseline

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Mismatch Negativity (MMN): E/I balance determined using MMN amplitude and latency measured using EEG.
Prazo: Baseline
Baseline
Relationship between E/I balance and auditory perceptual symptom severity, assessed using the Auditory Perceptual Trait and State Scale.
Prazo: Baseline
Baseline
EEG Resting-State Activity: Power across frequency bands (delta, theta, alpha, beta, gamma) during resting-state EEG.
Prazo: Baseline
Baseline
Auditory Oddball P300: Amplitude of the P300 event-related potential in response to an auditory oddball, measured using EEG.
Prazo: Baseline
Baseline
fMRI Resting-State Connectivity
Prazo: Baseline
E/I balance determined using functional connectivity between key brain regions (e.g., auditory cortex, prefrontal cortex) assessed by resting-state fMRI.
Baseline

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de setembro de 2026

Conclusão Primária (Estimado)

1 de agosto de 2030

Conclusão do estudo (Estimado)

1 de agosto de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

8 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de setembro de 2026

Primeira postagem (Real)

15 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

15 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

14 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Collected anonymised data may be shared with other researchers within and outside the UK as per open science agreements from the funder Wellcome.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever